Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
46 - Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
Summary
This chapter tells the story of one start-up biotech company that discovered and developed CT1812, a disease-modifying therapeutic for Alzheimer’s dieases that is currently in clinical trials. The company overcame significant financial and scientific challenges to discover and develop a drug candidate that works by a novel mechanism of action: CT1812 removes the toxic Aβ oligomers thought to cause AD from the site on brain cells where they create damage. The company went from an idea to five Phase 2 clinical trials. This case study will hopefully encourage other entrepreneurs to take this journey.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 513 - 523Publisher: Cambridge University PressPrint publication year: 2022
References
Patterson, C. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers. Available at: www.alz.co.uk/research/WorldAlzheimerReport2018.pdf (accessed January 29, 2021).Google Scholar
Heron, M. Deaths: leading causes for 2016. Available at: www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_06.pdf (accessed January 29, 2021).Google Scholar
Grabrucker, A, Vaida, B, Bockmann, J, Boeckers, TM. Synaptogenesis of hippocampal neurons in primary cell culture. Cell Tissue Res 2009; 338: 333–41.CrossRefGoogle ScholarPubMed
Ramakers, GJA, Kloosterman, F, van Hulten, P, van Pelt, J, Corner, MA. Activity-dependent regulation of neuronal network excitability. In Neural Circuits and Networks, Torre, V, Nicholls, J (eds.). Berlin: Springer; 1998: 141–51.Google Scholar
Banker, G, Goslin, K. Types of nerve cell cultures, their advantages, and limitations. In Culturing Nerve Cells, Banker, G, Goslin, K (eds.). Cambridge, MA: MIT Press; 1998: 11–36.Google Scholar
Opitz, T, De Lima, AD, Voigt, T. Spontaneous development of synchronous oscillatory activity during maturation of cortical networks in vitro. J Neurophysiol 2002; 88: 2196–206.Google Scholar
Torre, V, Nicholls, J (eds.). Neural Circuits and Networks. Heidelberg: Springer; 1998.CrossRefGoogle Scholar
LaBarbera, KM, Limegrover, CM, Rehak, C, et al. Modeling the mature CNS: a predictive screening platform for neurodegenerative disease drug discovery. J Neurosci Methods 2021; 358: 109180.Google Scholar
Kamenetz, F, Tomita, T, Hsieh, H, et al. APP processing and synaptic function. Neuron 2003; 37: 925–37.CrossRefGoogle ScholarPubMed
Lacor, PN, Buniel, MC, Chang, L, et al. Synaptic targeting by Alzheimer’s-related amyloid β oligomers. J Neurosci 2004; 24: 10191–200.Google Scholar
Reed, MN, Hofmeister, JJ, Jungbauer, L, et al. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 2011; 32: 1784–94.CrossRefGoogle ScholarPubMed
Hsieh, H, Boehm, J, Sato, C, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006; 52: 831–43.CrossRefGoogle ScholarPubMed
Hong, H-S, Maezawa, I, Yao, N, et al. Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity. Brain Res 2007; 1130: 223–34.Google Scholar
Kreutzmann, P, Wolf, G, Kupsch, K. Minocycline recovers MTT-formazan exocytosis impaired by amyloid beta peptide. Cell Mol Neurobiol 2010; 30: 979–84.Google Scholar
Liu, Y, Schubert, D. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J Neurochem 1997; 69: 2285–93.Google Scholar
Izzo, NJ, Staniszewski, A, To, L, et al. Alzheimer’s therapeutics targeting amyloid beta 1–42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One 2014; 9: e111898.CrossRefGoogle ScholarPubMed
Izzo, NNJ, Xu, J, Zeng, C, et al. Alzheimer’s therapeutics targeting amyloid beta 1–42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One 2014; 9: e111899.Google Scholar
Izzo, NJ, Yuede, CM, LaBarbera, KM, et al. Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer’s disease modification. Alzheimers Dement 2021;DOI: https://doi.org/10.1002/alz.12302.CrossRefGoogle Scholar
Rishton, GM, Look, G, Ni, Z-J, et al. Negative allosteric modulators of the sigma-2 receptor: discovery of investigational drug CT1812 for Alzheimer’s Disease. ACS Med Chem Lett; DOI: https://doi.org/10.1021/acsmedchemlett.1c00048.Google Scholar
Rishton, GM. Reactive compounds and in vitro false positives in HTS. Drug Discov Today 1997; 2: 382–4.CrossRefGoogle Scholar
Rishton, GM. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 2003; 8: 86–96.Google Scholar
Rishton, GM. Aggregator compounds confound amyloid fibrillization assay. Nat Chem Biol 2008; 4: 159–60.Google Scholar
Arai, H, Beierle, K, Fullenwider, C, Kaj, Z. Chemically conditioned extracts of ginger oil: leadlike “alkaloidal” compounds derived from natural extracts via reductive amination. American Chemical Society Western Regional Meeting, Anaheim, CA, Jan 22, 2006. Available at: http://acs.confex.com/acs/werm05/techprogram/S2455.HTM.Google Scholar
Grundman, M, Morgan, R, Lickliter, JD, et al. A Phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimers Dement (N Y) 2019; 5: 20–6.Google ScholarPubMed
Limegrover, CS, LeVine, H, Izzo, NJ, et al. Alzheimer’s protection effect of A673 T mutation may be driven by lower Aβ oligomer binding affinity. J Neurochem 2021; 157: 1316–30.Google Scholar
Masliah, E, Terry, RD, Alford, M, DeTeresa, R, Hansen, L. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer’s disease. Am J Pathol 1991; 138: 235–46.Google ScholarPubMed
DeKosky, ST, Scheff, SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457–64.Google Scholar
Scheff, SW, Price, DA. Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies. Neurobiol Aging 2003; 24: 1029–46.Google Scholar
Colom-Cadena, M, Spires-Jones, T, Zetterberg, H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alzheimers Res Ther 2020; 12: 21.Google Scholar
Riad, A, Zeng, C, Weng, C-CC, et al. Sigma-2 receptor/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex. Sci Rep 2018; 8: 16845.CrossRefGoogle ScholarPubMed
Riad, A, Lengyel-Zhand, Z, Zeng, C, et al. The sigma-2 receptor/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of Aβ42 and its protein aggregates. Mol Neurobiol 2020; 57: 3803–13.Google Scholar
Xu, J, Zeng, C, Chu, W, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011; 2: 380.Google Scholar
Alon, A, Schmidt, HR, Wood, MD, et al. Identification of the gene that codes for the σ 2 receptor. Proc Natl Acad Sci USA 2017; 114: 7160–5.CrossRefGoogle ScholarPubMed
Behrends, C, Sowa, ME, Gygi, SP, Harper, JW. Network organization of the human autophagy system. Nature 2010; 466: 68–76.CrossRefGoogle ScholarPubMed
Mir, SU, Schwarze, SR, Jin, L, et al. Progesterone receptor membrane component 1/sigma-2 receptor associates with MAP1LC3B and promotes autophagy. Autophagy 2013; 9: 1566–78.Google Scholar
Ahmed, IS, Rohe, HJ, Twist, KE, Craven, RJ. PGRMC1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010; 285: 24775–82.Google Scholar
Thomas, P, Pang, Y, Dong, J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology 2014; 155: 1107–19.Google Scholar
Zhang, M, Robitaille, M, Showalter, AD, et al. Progesterone receptor membrane component 1 is a functional part of the GLP-1 receptor complex in pancreatic beta cells. Mol Cell Proteomics 2014; 1: 3049–62.Google Scholar
Runko, E, Kaprielian, Z. Caenorhabditis elegans VEM-1, a novel membrane protein, regulates the guidance of ventral nerve cord-associated axons. J Neurosci 2004; 24: 9015–26.Google Scholar
Hampton, KK, Anderson, K, Frazier, H, Thibault, O, Craven, RJ. Insulin receptor plasma membrane levels increased by the progesterone receptor membrane component 1. Mol Pharmacol 2018; 94: 665–73.CrossRefGoogle ScholarPubMed
Mansouri, MR, Schuster, J, Badhai, J, et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet 2008; 17: 3776–83.Google Scholar
Sanchez-Pulido, L, Ponting, CP. TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease. Front Genet 2014; 5: 1–9.CrossRefGoogle ScholarPubMed
Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 300205:11/20/2019. Available at: https://omim.org/.Google Scholar
Ebrahimi-Fakhari, D, Wahlster, L, Bartz, F, et al. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann–Pick type C1 disease cells. Hum Mol Genet 2015; 25: 3588–99.Google Scholar
Intlekofer, KA, Clements, K, Woods, H, et al. Progesterone receptor membrane component 1 inhibits tumor necrosis factor alpha induction of gene expression in neural cells. PLoS One 2019; 14: e0215389.CrossRefGoogle ScholarPubMed
Rohe, HJ, Ahmed, IS, Twist, KE, Craven, RJ. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 2009; 121: 14–19.Google Scholar
Suchanek, M, Radzikowska, A, Thiele, C. Photo-leucine and photo-methionine allow identification of protein–protein interactions in living cells. Nat Methods 2005; 2: 261–7.Google Scholar
Hughes, AL, Powell, DW, Bard, M, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007; 5: 143–9.Google Scholar
Limegrover, CS, Yurko, R, Izzo, NJ, et al. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain-derived α-synuclein. J Neurosci Res 2021; 99: 1161–76.Google Scholar
Izzo, NJ, Colom-Cadena, M, Riad, AA, et al. Proceedings from the Fourth International Symposium on Sigma-2 Receptors: Role in Health and Disease. eNeuro 2020; 7: 1–7. Available at: http://eneuro.org/lookup/doi/10.1523/ENEURO.0317-20.2020.CrossRefGoogle ScholarPubMed
Frautschy, SA, Cole, GM. Why pleiotropic interventions are needed for Alzheimer’s disease. Mol Neurobiol 2010; 41: 392–409.Google Scholar